A PHASE Ia/Ib, OPEN LABEL, MULTICENTER, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF RO7502175 AS A SINGLE AGENT AND IN COMBINATION WITH CHECKPOINT INHIBITOR IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Primary Objective

This is a first-in-human study to learn about the investigational drug called RO7502175.

Is This Study For You?

Let's Get Started!

Description

Participants will be enrolled in 2 stages: dose escalation and dose expansion.

Details
Age
Adult
Eligibility
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study
Locations

CTRC Inpatient
University of Colorado Hospital

Principal Investigator
Photograph of Antonio Jimeno

Antonio Jimeno

Study ID

Protocol Number: 22-1245

More information available at ClinicalTrials.gov: NCT05581004

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers